+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 7 Actively Recruiting clinical trials

A

Actively Recruiting

Researchers are evaluating whether combining tucatinib with trastuzumab and mFOLFOX6 works better than standard treatments for people with HER2 positive colorectal cancer that has spread or cannot be removed by surgery. This Phase 3 study also aims to learn about the side effects that may occur when taking this combination of drugs. Participants have metastatic or unresectable colorectal cancer and are randomly assigned to different treatment groups. Participants are randomly placed in one of two study groups. One group receives tucatinib taken orally twice daily along with trastuzumab given intravenously every 3 weeks and mFOLFOX6 chemotherapy every 2 weeks. The other group receives standard care, which may be mFOLFOX6 alone or combined with bevacizumab or cetuximab, both given intravenously on different schedules. Tissue samples and biopsies are collected before treatment to confirm HER2 positivity and other markers. During the study, participants will have regular evaluations including imaging scans to measure cancer progression, blood tests, and assessments of side effects and quality of life. Progression-free survival is the primary outcome measured for up to about 3 years, with other outcomes like overall survival and response rate also tracked. Safety monitoring continues for about one year after the last treatment. The study lasts several years, with ongoing follow-up to understand long-term effects and benefits.

Age: 18Years +All GendersPhase 3
366 locations
R

Actively Recruiting

Researchers are evaluating whether the drug PF-08046054 works better alone compared to the standard chemotherapy docetaxel in adults with non-small cell lung cancer NSCLC who have tumors expressing PD-L1 at 1% or higher. These participants have cancer that has spread in their body or cannot be removed by surgery or treated with radiation. All participants must have experienced disease progression during or after treatment with PD-L1 or PD-1 inhibitors, platinum-based chemotherapy, and targeted therapies if they have specific genetic mutations. Participants are randomly assigned to one of two groups. One group receives PF-08046054 through an intravenous IV infusion twice every 21-day cycle, while the other group receives docetaxel as an IV infusion once every 21 days. The study may last up to 5 years if the participants cancer responds to treatment. This phase 3 study compares the two therapies to understand their impact on survival and disease progression. During the study, participants will visit the clinic regularly to monitor their health and response to treatment. Researchers will measure overall survival and other outcomes such as progression-free survival, response rates, duration of response, and quality of life using questionnaires. Safety will also be monitored through adverse event evaluations. The study includes biomarker analysis using tumor tissue samples and tracks drug levels and immune responses over time.

Age: 18Years +All GendersPhase 3
447 locations
A

Actively Recruiting

Researchers are studying a new medicine called PF-08634404 to see how well it works in adults with metastatic colorectal cancer, which is cancer that has spread to other parts of the body. The study compares PF-08634404 combined with approved chemotherapy to an approved medicine called Bevacizumab combined with chemotherapy. The goal is to understand if the new medicine can improve outcomes for people whose cancer has spread or returned after previous treatments. Participants are randomly assigned to one of two treatment groups. One group receives PF-08634404 with chemotherapy, and the other group receives Bevacizumab with chemotherapy. All medicines are given through intravenous IV infusions at a clinical site. Treatment is given in cycles, and participants may continue treatment as long as it is helping and side effects are manageable. After treatment ends, participants return for a final visit around 30 to 37 days later. During the study, participants have regular visits for treatment, health checks, and tests. Follow-up continues every 12 weeks through phone, in-person visits, or health record reviews to monitor health status and any new treatments. Researchers will measure outcomes such as progression-free survival, overall survival, response rates, side effects, quality of life, and drug levels. The study is expected to last about 33 months per participant.

Age: 18Years +All GendersPhase 3
372 locations
S

Actively Recruiting

Researchers are studying a new medicine called PF-08634404 for adults with locally advanced or metastatic urothelial cancer, a type of bladder cancer that has spread to nearby tissues or other parts of the body. The study aims to evaluate the safety, effectiveness, and behavior of PF-08634404 in the body, as well as how it affects cancer-related markers. This trial includes adults aged 18 and older who have this type of cancer. The study has two groups Cohort A includes participants who have already received treatment and will receive PF-08634404 alone. Cohort B includes participants who have not had prior treatment and will receive PF-08634404 combined with another cancer medicine called enfortumab vedotin. Both treatments are given through intravenous infusion. Treatment continues as long as it benefits the participant and side effects are manageable. Participants will undergo a screening period to confirm eligibility before starting treatment. During the study, they will have regular visits for treatment, health assessments, scans to monitor cancer progress, and laboratory tests. Researchers will measure outcomes such as the cancers response to treatment, side effects, survival, and drug levels in the body. If the cancer worsens but treatment remains helpful and tolerable, participants may continue treatment with agreement from their doctor and the sponsor. The study follows participants for up to approximately three years.

Age: 18Years +All GendersPhase 1Phase 2
184 locations
S

Actively Recruiting

Researchers are evaluating a new medicine called PF-08634404 in adults with advanced Renal Cell Carcinoma RCC, a type of kidney cancer that has spread locally or to other parts of the body. This study aims to assess the safety of PF-08634404 given alone or combined with other anticancer drugs and to observe how the cancer responds. Participants must be adults with locally advanced or metastatic RCC who have not received treatment for advanced kidney cancer before joining. Participants will be randomly assigned to receive one of four treatments PF-08634404 alone, PF-08634404 with ipilimumab, PF-08634404 with axitinib, or PF-08634404 with Casdatifan. All medications are administered through intravenous infusions or tablets as appropriate, given at clinical study sites by trained medical staff. The study includes treatment and evaluation phases lasting up to approximately three years. During the study, participants will have regular assessments including scans following RECIST v1.1 guidelines to measure tumor response. Researchers will monitor treatment safety by tracking adverse events, dose-limiting toxicities, and laboratory test results. Pharmacokinetics and immune response to the study drug will also be evaluated. These measures will continue through treatment and up to 90 days after the last intervention, with follow-up for up to three years to assess overall survival and progression-free survival.

Age: 18Years +All GendersPhase 1Phase 2
183 locations
G

Actively Recruiting

Researchers are studying a new medicine called PF-08634404 to see how well it works when combined with chemotherapy in adults who have extensive-stage small cell lung cancer ES-SCLC, a fast-growing type of lung cancer that has spread widely. This study includes two parts the first part focuses on checking the safety and tolerance of the medicine with chemotherapy, while the second part compares this combination to an approved treatment using atezolizumab and chemotherapy. Participants will receive treatments through intravenous infusions in repeated cycles. Some participants may continue receiving PF-08634404 alone after the initial combined treatment phase. The study involves random assignment to either the PF-08634404 plus chemotherapy group or the atezolizumab plus chemotherapy group. During the study, participants will have regular assessments including scans to measure tumor response, physical exams, laboratory tests, and questionnaires to evaluate quality of life. The researchers will track outcomes such as tumor shrinkage, overall survival, adverse events, and treatment tolerance up to about two years after treatment completion. Safety and drug concentration in the blood will also be monitored closely throughout the trial.

Age: 18Years +All GendersPhase 2Phase 3
82 locations
R

Actively Recruiting

Researchers are evaluating whether combining the investigational drug mevrometostat PF-06821497 with enzalutamide works better than enzalutamide alone in men with metastatic castration-sensitive prostate cancer mCSPC who have not received androgen receptor pathway inhibitors or chemotherapy for mCSPC. This Phase 3, global, multicenter, randomized, double-blind, placebo-controlled study focuses on participants with prior limited androgen-deprivation therapy and no disease progression or rising PSA before treatment starts. Participants are randomly assigned to one of two groups one receives mevrometostat 875 mg twice daily plus enzalutamide 160 mg once daily, and the other receives a placebo plus enzalutamide at the same dose. The study includes a screening phase, treatment phase, safety follow-up, and long-term follow-up. Treatment is oral and taken continuously during the trial. During the study, participants undergo various assessments including imaging scans to track disease progression, laboratory tests, and patient-reported questionnaires on pain, quality of life, and fatigue. Researchers will monitor radiographic progression-free survival for up to about 4 years and overall survival for up to about 9 years. Safety and pharmacokinetics of mevrometostat combined with enzalutamide are also evaluated. The total duration includes screening, treatment, safety monitoring, and extended follow-up phases.

Age: 18Years +MALEPhase 3
319 locations